NASDAQ:AMAG - AMAG Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$11.91 +0.08 (+0.68 %)
(As of 04/23/2019 06:00 AM ET)
Previous Close$11.83
Today's Range$11.77 - $12.06
52-Week Range$10.70 - $26.10
Volume398,295 shs
Average Volume683,482 shs
Market Capitalization$401.93 million
P/E RatioN/A
Dividend YieldN/A
Beta0.42
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company's products candidates include Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women; AMAG-423, a polyclonal antibody in development for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent for the treatment of oral anticoagulants or low molecular weight heparin. It sells Feraheme to authorized wholesalers and specialty distributors. The company has a license agreement with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio LLC, Perosphere Pharmaceuticals Inc., Antares Pharma, Inc., and Abeona Therapeutics, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Receive AMAG News and Ratings via Email

Sign-up to receive the latest news and ratings for AMAG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMAG
CUSIP00163U10
Phone617-498-3300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$474 million
Cash Flow$1.5901 per share
Book Value$21.62 per share

Profitability

Net Income$-65,760,000.00

Miscellaneous

Employees467
Market Cap$401.93 million
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable

AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions

What is AMAG Pharmaceuticals' stock symbol?

AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."

How were AMAG Pharmaceuticals' earnings last quarter?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) issued its earnings results on Thursday, February, 7th. The specialty pharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.98) by $0.38. The specialty pharmaceutical company earned $88.10 million during the quarter, compared to the consensus estimate of $95.21 million. AMAG Pharmaceuticals had a negative net margin of 13.07% and a negative return on equity of 17.10%. AMAG Pharmaceuticals's revenue was down 31.4% on a year-over-year basis. During the same period last year, the business posted $0.10 EPS. View AMAG Pharmaceuticals' Earnings History.

When is AMAG Pharmaceuticals' next earnings date?

AMAG Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for AMAG Pharmaceuticals.

What guidance has AMAG Pharmaceuticals issued on next quarter's earnings?

AMAG Pharmaceuticals issued an update on its FY 2019 earnings guidance on Thursday, February, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $365-415 million, compared to the consensus revenue estimate of $382.51 million.

What price target have analysts set for AMAG?

9 equities research analysts have issued 12-month price objectives for AMAG Pharmaceuticals' stock. Their forecasts range from $14.00 to $24.65. On average, they anticipate AMAG Pharmaceuticals' share price to reach $20.2063 in the next twelve months. This suggests a possible upside of 69.7% from the stock's current price. View Analyst Price Targets for AMAG Pharmaceuticals.

What is the consensus analysts' recommendation for AMAG Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AMAG Pharmaceuticals in the last year. There are currently 1 sell rating, 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AMAG Pharmaceuticals.

What are Wall Street analysts saying about AMAG Pharmaceuticals stock?

Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "AMAG reported a loss in the fourth quarter, narrower than the Zacks Consensus Estimate while sales missed estimates. The company achieved two key regulatory milestones in 2018, with the FDA approving the label expansions of Feraheme and Makena, and accepting the NDA for Vyleesi. During the second half of 2018, the company broadened its product pipeline by adding two promising development-stage assets — AMAG-423, an orphan drug for the potential treatment of severe preeclampsia and thein-licensing of Intrarosa. The company divested the Cord Blood Registry (CBR) business and strengthened its balance sheet. However, in July, Makena’s generic hit the market, which pulled down the drug’s sales. Feraheme currently competes with IV iron replacement therapies like Venofer, Injectafer, Ferrlecit and their generic versions, among others. Shares of the company have underperformed the industry year to date." (3/20/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our Neutral rating and are lowering our PT to $14 from $17. Failure of the post-approval Makena trial is a clear setback for the company. We suspect investors may be increasingly drawn to the stock as one to own given the subsequent devaluation, but that longer-term investing requires some framing of the commercial impact. We believe the trial result reinforces the importance of the next 12-18 months for AMAG to demonstrate that existing and pipeline assets can adequately replace lost Makena revenue." (3/14/2019)

Has AMAG Pharmaceuticals been receiving favorable news coverage?

Media coverage about AMAG stock has been trending negative on Tuesday, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AMAG Pharmaceuticals earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the next several days.

Who are some of AMAG Pharmaceuticals' key competitors?

What other stocks do shareholders of AMAG Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AMAG Pharmaceuticals investors own include Celgene (CELG), Broadcom (AVGO), Bausch Health Companies (BHC), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), bluebird bio (BLUE), Micron Technology (MU), Skyworks Solutions (SWKS) and Alibaba Group (BABA).

Who are AMAG Pharmaceuticals' key executives?

AMAG Pharmaceuticals' management team includes the folowing people:
  • Dr. William K. Heiden, CEO, Pres & Director (Age 59)
  • Mr. Edward H. Myles, Exec. VP & CFO (Age 47)
  • Mr. Joseph D. Vittiglio, Exec. VP of Legal Affairs and Quality, Gen. Counsel & Sec. (Age 47)
  • Dr. Julie Krop, Exec. VP of Devel. & Chief Medical Officer (Age 53)
  • Mr. Nicholas Grund, Exec. VP & Chief Commercial Officer (Age 49)

Who are AMAG Pharmaceuticals' major shareholders?

AMAG Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Strs Ohio (0.15%) and Tibra Equities Europe Ltd (0.10%). Company insiders that own AMAG Pharmaceuticals stock include Joseph Vittiglio, Julie Krop and William K Heiden. View Institutional Ownership Trends for AMAG Pharmaceuticals.

Which major investors are buying AMAG Pharmaceuticals stock?

AMAG stock was bought by a variety of institutional investors in the last quarter, including Tibra Equities Europe Ltd and Strs Ohio. View Insider Buying and Selling for AMAG Pharmaceuticals.

How do I buy shares of AMAG Pharmaceuticals?

Shares of AMAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AMAG Pharmaceuticals' stock price today?

One share of AMAG stock can currently be purchased for approximately $11.91.

How big of a company is AMAG Pharmaceuticals?

AMAG Pharmaceuticals has a market capitalization of $401.93 million and generates $474 million in revenue each year. The specialty pharmaceutical company earns $-65,760,000.00 in net income (profit) each year or ($3.88) on an earnings per share basis. AMAG Pharmaceuticals employs 467 workers across the globe.

What is AMAG Pharmaceuticals' official website?

The official website for AMAG Pharmaceuticals is http://www.amagpharma.com.

How can I contact AMAG Pharmaceuticals?

AMAG Pharmaceuticals' mailing address is 1100 WINTER STREET, WALTHAM MA, 02451. The specialty pharmaceutical company can be reached via phone at 617-498-3300 or via email at [email protected]


MarketBeat Community Rating for AMAG Pharmaceuticals (NASDAQ AMAG)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  333 (Vote Outperform)
Underperform Votes:  445 (Vote Underperform)
Total Votes:  778
MarketBeat's community ratings are surveys of what our community members think about AMAG Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMAG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMAG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel